1-(5-溴吡啶-2-基)环丙烷甲腈 | 827628-15-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-(5-溴吡啶-2-基)环丙烷甲腈
• 英文名称: 1-(5-bromopyridin-2-yl)cyclopropane-1-carbonitrile
• 英文别名: 1-(5-bromopyridin-2-yl)cyclopropanecarbonitrile；1-(5-bromo-2-pyridyl)cyclopropanecarbonitrile
• CAS: 827628-15-9
• 化学式: C₉H₇BrN₂
• 分子量: 223.072
• InChiKey: GGRMZTUSQIMIPA-UHFFFAOYSA-N

物化性质

• 熔点：
  93.5-94.5 °C
• 沸点：
  336.1±37.0 °C(Predicted)
• 密度：
  1.62±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(5-Bromopyridin-2-yl)cyclopropane-1-carbonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(5-Bromopyridin-2-yl)cyclopropane-1-carbonitrile
CAS number: 827628-15-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H7BrN2
Molecular weight: 223.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(5-溴吡啶-2-基)环丙烷甲腈 在 水 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.33h， 生成 1-(5-bromo-pyridin-2-yl)-cyclopropanecarboxylic acid methylamide
  参考文献：
  名称：

  [EN] SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE
  [FR] HÉTÉROCYCLES À 5, 6 ET 7 CHAÎNONS SUBSTITUÉS, MÉDICAMENTS CONTENANT CES COMPOSÉS ET LEUR UTILISATION

  摘要：

  本发明涉及由以下式I定义的化合物：其中变量A1、A2、Cy1、Cy2、Cy3、E、R1a、R1b、R2、R3、n和Q如本文所定义，具有有价值的药理活性。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。

  公开号：

  WO2011159760A1
• 作为产物：
  描述：

  2-氟-5-溴吡啶 、 环丙基腈 在 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 以70 %的产率得到1-(5-溴吡啶-2-基)环丙烷甲腈
  参考文献：
  名称：

  通过（杂）脂肪族腈的 α-芳基化多克合成 α-和 γ-（（杂）环）烷基吡啶

  摘要：

  (环)烷基吡啶：描述了用 2- 和 4- 氟吡啶衍生物对腈和酯阴离子进行S N Ar 芳基化的系统研究。结合水解和脱羧，该方法为多克合成在 α 或 γ 位上用烷基、环烷基和饱和杂环取代基修饰的官能化吡啶提供了一种有效的方法，这些取代基是药物化学的重要组成部分。

  DOI：

  10.1002/ejoc.202300538

文献信息

• [EN] BTK INHIBITORS<br/>[FR] INHIBITEURS DE LA BTK
  申请人：MERCK SHARP & DOHME

  公开号：WO2016109215A1

  公开（公告）日：2016-07-07

  The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

  本发明提供了根据式(I)提供的Bruton's酪氨酸激酶（Btk）抑制剂化合物，或其药学上可接受的盐或立体异构体，或包含这些化合物的药物组合物，并且用于治疗的使用。具体而言，本发明涉及在治疗Btk介导的疾病中使用式(I)的Btk抑制剂化合物。
• [EN] BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS<br/>[FR] DÉRIVÉS D'OXADIAZOLOPYRIDINE À SUBSTITUTION BENZYLE, (PYRIDIN-3-YL)MÉTHYLE OU (PYRIDIN-4-YL)MÉTHYLE UTILISÉS EN TANT QU'INHIBITEURS DE LA GHRÉLINE O-ACYLTRANSFÉRASE (GOAT)
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2019149657A1

  公开（公告）日：2019-08-08

  The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.

  本发明涉及一般式（I）的化合物，其中基团R1和R2的定义如权利要求1中所述，该化合物具有有价值的药理特性，特别是与胃饥饿素O-酰基转移酶（GOAT）结合并调节其活性。这些化合物适用于治疗和预防可以受到该受体影响的疾病，如代谢性疾病，特别是肥胖症。
• [EN] DIACYLGLYCEROL KINASE MODULATING COMPOUNDS<br/>[FR] COMPOSÉS MODULANT LA DIACYLGLYCÉROL KINASE
  申请人：CARNA BIOSCIENCES INC

  公开号：WO2021130638A1

  公开（公告）日：2021-07-01

  The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

  本公开提供了调节二酰基甘油激酶的化合物以及用于治疗癌症（包括实体瘤）和病毒感染（如HIV或乙型肝炎病毒感染）的药物组合物。这些化合物可以单独使用或与其他药物联合使用。
• Mild and Practical Method for the α-Arylation of Nitriles with Heteroaryl Halides
  作者：Artis Klapars、Jacob H. Waldman、Kevin R. Campos、Mark S. Jensen、Mark McLaughlin、John Y. L. Chung、Raymond J. Cvetovich、Cheng-yi Chen

  DOI：10.1021/jo051737f

  日期：2005.11.1

  aliphatic nitriles with activated heteroaryl halides was developed using NaHMDS or KHMDS as base at ambient temperature. The key to the success of this method is generation of the nitrile anion in the presence of the heteroaryl halide. The method is applicable to both primary and secondary carbonitriles and a wide range of heteroaryl halides. Selective monoarylation was observed with primary carbonitriles

  在环境温度下，以NaHMDS或KHMDS为碱，开发了一种温和且无过渡金属的方法，用于将脂族腈与活化的杂芳基卤化物进行α-芳基化。该方法成功的关键是在杂芳基卤化物存在下生成腈阴离子。该方法适用于伯腈和仲腈以及各种杂芳基卤化物。在伯腈中观察到选择性单芳基化。操作简便和温和的反应条件增加了该方法的价值，可作为制备α-杂芳基腈的一种实用选择。
• [EN] COMPOUNDS FOR USE AS GPR120 AGONISTS<br/>[FR] COMPOSÉS POUVANT ÊTRE UTILISÉS À TITRE D'AGONISTES DE GPR120
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2015125085A1

  公开（公告）日：2015-08-27

  The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, geometrical isomer, prodrug, carboxylic acid isostere, solvate, polymorph, N-oxide, S-oxide or pharmaceutically acceptable salt thereof, which are GPR120 agonists. The present invention also relates to a pharmaceutical composition of a compound of formula (I) for the treatment of metabolic disorders, particularly Type 2 diabetes and associated diseases.

  本发明涉及一种式（I）的化合物，或其互变异构体、立体异构体、几何异构体、前药、羧酸同工体、溶剂合物、多形体、N-氧化物、S-氧化物或其药学上可接受的盐，它们是GPR120激动剂。本发明还涉及一种式（I）的化合物的药物组合物，用于治疗代谢紊乱，特别是2型糖尿病及相关疾病。